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OBJECTIVES We sought to investigate the effect of a catheter-mounted microaxial blood pump (Impella,
Aachen, Germany) on myocardial infarct size.
BACKGROUND The small rotary blood pump Impella provides unloading of the left ventricle and is
introducible via the femoral artery.
METHODS Myocardial infarction was induced by occlusion of major branches of the left anterior
descending coronary artery for 60 min followed by 120 min of reperfusion in 26 sheep. The
animals were allocated to four groups: group 1 had no support; group 2 was fully supported
with the pump during ischemia and reperfusion; group 3 was supported during reperfusion
only; and group 4 was partially supported during reperfusion. Infarct size, hemodynamics,
myocardial oxygen consumption, lactate extraction, and myocardial flow were analyzed.
RESULTS Infarct size was significantly reduced in the pump-supported animals (percent area at risk in
group 1: 67.2  4.6%; group 2: 18.1  10%; group 3: 41.6  5.8%; group 4: 54  8%; p 
0.00001). The pump produced 4.1  0.1 l/min at full support and 2.4  0.1 l/min at partial
support. The pump significantly increased the diastolic and mean blood pressures (groups 2,
3, and 4) and significantly decreased the left ventricular end-diastolic pressure (groups 2 and
3). During ischemia, myocardial flow was not influenced by pump support. At reperfusion,
the fully supported group had significantly higher myocardial flow. Pump support reduced
myocardial oxygen consumption significantly, and this reduction correlates strongly with the
reduction in infarct size (r  0.9).
CONCLUSIONS Support by a microaxial blood pump reduces myocardial oxygen consumption during
ischemia and reperfusion and leads to a reduction of infarct size. This reduction in infarct size
correlates with the degree of unloading during reperfusion. (J Am Coll Cardiol 2003;41:
1087–95) © 2003 by the American College of Cardiology Foundation
The transvalvular assist device Impella (Aachen, Germany)
is a potent, miniaturized pump that offers the possibility of
unloading the left ventricle (LV) via the femoral placement
(1). In vivo and clinical use of this device has indicated that
the pump produces a mean flow of 4.2 l/min at maximal
rotational speed (2).
Mechanical unloading of the myocardium during isch-
emia and reperfusion has been shown to reduce LV pressure
work and myocardial oxygen consumption (3–5). However,
the installation of a left heart bypass during myocardial
infarction (MI) is a cumbersome clinical procedure, with
important comorbidity.
Pharmacologic approaches, such as the early use of
beta-blockers, nitroglycerin, and angiotensin-converting en-
zyme inhibitors, have achieved infarct size reduction in
experimental models (6–10). The use of beta-blockers and
angiotensin-converting enzyme inhibitors has rapidly ad-
vanced from experimental studies to the clinical recommen-
dation as standard therapy in most patients experiencing an
MI. However, clinical trials on the early use (first day of
infarction) showed an increased incidence of hypotension
(9–12).
Mechanical support combines the beneficial effects of
myocardial unloading and an increase in perfusion pressure.
It can therefore be used early, even during ischemia and in
myocardial failure.
This new pump allows unloading of the LV via a
peripheral approach in the setting of acute MI. We wanted
to investigate the effect of this microaxial blood pump on
MI size.
METHODS
Studies were carried out in 26 adult Dorset sheep weighing
68.5  8.7 kg. The study protocol was approved by the
Ethical Committee for Laboratory Animals of the Catholic
University of Leuven, and all experiments were performed
according the Committee’s guidelines.
The microaxial blood pump. The Impella LV support
system is a miniaturized rotary blood pump (diameter
6.4 mm). The pump incorporates a rotor driven by an
electrical motor and has an inflow cannula (Fig. 1). The
pump is placed through the aortic valve and aspirates blood
from the LV cavity and expels it in the ascending aorta. The
performance of this pump depends on the rotary speed
(which is maximized at 32,000 rotations/min) and the
pressure head which the pump has to face (1). In the clinical
condition, this pressure head equals the aortic blood pres-
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sure (BP) minus the LV pressure. A pressure sensor is
located in front of the rotor and continuously registers this
pressure difference. This pressure signal is an indicator of
the correct position of the pump. The pump flow produced
in physiologic conditions at maximal rotational speed is in
the range of 4.2 to 4.6 l/min. The driving console of the
pump allows the management of pump speed (by 9 grada-
tions) and displays the pressure difference between inflow
and outflow.
The pump is approved as safe for human use up to seven
days. The pump is clinically used in the support of coronary
artery bypass grafting and in postcardiotomy heart failure.
The feasibility of this pump was tested in a randomized,
multicenter trial in 200 patients (13). The inflammatory
response in patients who had an operation with pump
support was significantly reduced compared with the control
group, whose operation involved the heart-lung machine.
Placement of the LV support system was uneventful, and no
aortic insufficiency was shown with the pump in the
transvalvular position.
Surgical preparation. Animals were premedicated with
ketamine (15 mg/kg intramuscularly). General anesthesia
was induced and maintained with 0.5% to 2.0% halothane.
The animals were intubated and mechanically ventilated by
an Engstro¨m II respirator (Datex Ohmeda, Stockholm,
Sweden) with room air supplemented with oxygen to
maintain arterial blood gasses in the physiologic range.
Surface electrocardiographic (ECG) leads were applied, a
gastric tube inserted, and a fluid-filled catheter placed in the
left ear artery to enable monitoring of the vital parameters.
A left thoracotomy was performed in the fourth intercostal
space. The pericardium was opened, and the heart was
suspended in a pericardial cradle. A 6-mm ultrasonic transit
time flow probe was placed around the left main coronary
artery (Transonic Inc., Ithaca, New York), and a 20-mm
probe was placed around the pulmonary artery. A
micromanometer-tipped catheter transducer (Millar Instru-
ments, Inc., Houston, Texas) was placed in the LV cavity
through the apex of the heart. Fluid-filled catheters were
placed in the left atrium, jugular vein, and coronary sinus.
The hemiazygos vein was ligated.
The micropump was inserted via the carotid artery
(cut-down), and the entrance of the inflow cannula in the
LV was checked by the differential pressure signal. Snares
were placed around the two first diagonal branches of the
left anterior descending coronary artery.
Experimental protocol. Baseline measurements included
hemodynamic values (arterial BP, cardiac output, left atrial
pressure, LV pressure, first derivative of LV pressure),
coronary flow, arterial and coronary sinus blood gas analysis,
and lactate sampling. Two major diagonal branches of the
left anterior descending coronary artery were ligated for 1 h.
Reperfusion was allowed for 2 h. Hemodynamic values and
flow data were continuously recorded. Sampling for blood
gasses and lactate content was done at baseline and at 5, 30,
and 60 min of ischemia; at 5, 30, 60, and 120 min of
reperfusion; and 5 min after the pump was stopped. Group
1 (n  8) served as a control group, and no support was
given. In group 2 (n  6), the Impella pump was started at
maximal rotational speed from the moment of ischemia
until the completion of 2 h of reperfusion. In group 3 (n 
6), ventricular support was started at the moment of
reperfusion. In group 4 (n  6), ventricular support was
again started at reperfusion, but only half of the baseline
cardiac output was provided by the pump (so-called “partial
support”).
Myocardial oxygen consumption. The left coronary artery
in sheep exclusively supplies the entire LV, with minimal
overlap to the right ventricle (RV) (14,15). All venous blood
from the LV drains into the coronary sinus, whereas venous
blood from the RV does not drain into the coronary sinus,
but goes directly to the right atrium (16). Thus, measure-
Abbreviations and Acronyms
BP  blood pressure
CBF  coronary blood flow
Hb  hemoglobin
LER  lactate extraction ratio
LV  left ventricle/ventricular
MI  myocardial infarction/infarct
RV  right ventricle/ventricular
TTC  triphenyltetrazolium chloride
Figure 1. The microaxial blood pump has an outer diameter of 6.4 mm and
is driven by a miniaturized electrical motor incorporated in the housing.
The cannula (upper panel) is placed across the aortic valve, and the pump
aspirates the blood from the left ventricular cavity to expel it in the
ascending aorta. A differential pressure sensor (lower panel) continuously
measures the pressure difference between the inflow and outflow of the
pump and allows the calculation of the produced pump flow.
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ment of the left main coronary blood flow (CBF) represents
total blood flow to the LV, and the arterio-coronary sinus
oxygen content difference reflects the amount of oxygen
utilized by the LV. For determination of myocardial oxygen
consumption, aortic and coronary sinus blood samples were
drawn simultaneously into heparinized syringes. The hemo-
globin (Hb) concentration, oxygen partial pressure (PO2),
and blood saturation (SaO2) were immediately analyzed with
an automatic blood gas, oximetry, electrolyte, and metabo-
lite analyzer (ABL System 625 Radiometer Medical A/S,
Copenhagen, Denmark).
Left ventricular myocardial oxygen consumption (MVO2)
was normalized to LV weight and expressed in ml/min per
100 g of LV mass. It was defined as a product of mean left
main CBF, and the difference in oxygen content between
arterial (aO2) and coronary sinus (VO2) blood was expressed
in ml O2/dl of blood:
MVO2  (aO2  VO2)  CBF
The oxygen content in arterial and venous blood was
calculated as a sum of oxygen transported by Hb and oxygen
dissolved in blood plasma. The oxygen transported by sheep
Hb equals 1.35  Hb concentration (g/dl)  blood satu-
ration (17). Oxygen dissolved in plasma was calculated as
oxygen partial pressure (mm Hg)  0.0031 (oxygen solu-
bility coefficient in blood plasma at 37°C) (18). Oxygen
content in blood was expressed in ml O2/dl of blood:
aO2 (VO2)  (1.35  Hb  sO2/100%)  (pO2  0.0031)
Lactate metabolism. The balance between aerobic and
anaerobic myocardial metabolism was studied based on
lactate metabolism (19). The arterial blood lactate concen-
tration and coronary sinus lactate concentration were mea-
sured with an automatic blood gas, oximetry, electrolyte,
and metabolite analyzer (ABL System 625).
The lactate extraction ratio (LER), expressed as percent-
age, represents the amount of lactate that is extracted by the
LV from arterial blood. It is calculated by dividing the
arterio-coronary sinus lactate concentration difference by
the lactate concentration in arterial blood:
LER  (AL  VL)  100%/AL
where AL is arterial lactate and VL is venous lactate.
Positive values indicate lactate uptake, and negative
values represent lactate released into coronary sinus blood.
MI size determination. Upon termination of the experi-
ment, the hearts were arrested by potassium chloride. The
snares around the target coronary arteries were re-occluded.
The aorta was cross-clamped, and a catheter was inserted
into the aortic root. First, 500 ml of saline solution and then
500 ml of Evans’ blue dye were administered by a contin-
uous infusion at a perfusion pressure of 100 mm Hg. The
right and left atria were opened to allow free drainage of
blood and stain. The hearts were removed and cut in
1-cm-thick slices perpendicular to the long axis, and the
slices were placed in a bath of 1% triphenyltetrazolium
chloride (TTC) at 37°C during 5 min to allow staining of
the infarct-related areas.
After staining, the RV, both atria, and the valvular
apparatus were excised. The complete heart, LV, and each
LV slice were weighed separately. Both surfaces of each slice
were photographed. Measurement of the area at risk and
infarct size was performed by computer-assisted planimetry.
The weights of measured areas was analyzed: the area at risk
was expressed as the percent of LV mass, and infarct size
was expressed as the percent of area at risk (20).
Myocardial blood flow. Myocardial flow was analyzed
with the colored microspheres technique (21). At baseline,
at 30 min of ischemia, at 60 min of reperfusion, and at
5 min after the pump was stopped, a set of 9 million of
15 m colored polystyrene microspheres (Triton Technol-
ogy, Inc., San Diego, California) was injected through a left
atrial catheter. Arterial reference blood was withdrawn over
90 s from the aorta at a flow rate of 10 ml/min. Upon
termination of the experiment, 1-g tissue samples were
isolated from the different regions of the myocardium.
Subendocardial and subepicardial samples were taken from
the area at risk and from the lateral wall (control area). The
microspheres were recovered from the tissue samples by
digestion of the tissue by KOH. Subsequently, the samples
were filtered, dye-extracted, and examined by spectropho-
tometry.
Data analysis. All pressure transducers were connected to a
Triton pressure module. The hemodynamic and ECG
parameters were recorded on-line on an eight-channel chart
recorder (Nyhon Kohden, Tokyo, Japan) and continuously
registered and displayed on a Pentium II Dell computer
using Labview software (National Instruments, Austin,
Texas). Hemodynamic parameters were automatically reg-
istered in 60-s intervals.
Continuous data are presented as the mean value  SD.
Direct comparisons with the control group were analyzed
with the Student t test (Statistica, Tulsa, Oklahoma). Data
on oxygen metabolism were analyzed with analysis of
variance with repeated measures for time (Statistica). In case
of a significant difference (p  0.05) between groups, the
Newman-Keuls test was used for post-hoc testing. This test
corrects for multiple testing.
RESULTS
Hemodynamic changes. The hemodynamic evolution
during ischemia and reperfusion is summarized in Table 1.
Based on the relative small area of ischemia, the general
hemodynamic effect of coronary occlusion was mild. There
was a slight decrease in cardiac output and mean BP and an
increase in filling pressure. None of these changes are
significant.
The pump produced 4.1  0.4 l/min at the maximal
rotational speed. Initiation of the pump resulted in unload-
ing, as indicated by a significant decrease in LV end-
diastolic pressure, left atrial pressure, and first derivative of
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LV pressure. In addition, the diastolic BP was significantly
increased, leading to an increase in mean perfusion pressure
(from 78  4 to 83  4 mm Hg).
Support with reduced pump performance (group 4) led to
a significant increase in mean BP but did not decrease the
preload significantly.
Myocardial metabolism. Myocardial oxygen consumption
was significantly influenced during the experiment (Fig. 2).
The changes are significant in time and for the different
groups in the evolution over time (p  0.000001). At
reperfusion, myocardial oxygen consumption increased
slightly.
The animals assisted with the pump showed an immedi-
ate and significant reduction in oxygen consumption. The
degree of reduction was similar during ischemia and reper-
fusion. The reduction was more explicit when the pump was
used at full performance. The effect of partial support (group
4) still resulted in a significant reduction in myocardial
oxygen consumption (p  0.000016).
General myocardial metabolism is well indicated by the
LER (Fig. 2). The LER changed significantly during the
experiment. These changes are significant in time and in
relation to the support group (p  0.003). However, the
difference is only significant for the fully supported group
during ischemia. The LER in the supported groups during
reperfusion was not significantly increased, as compared
with the control group.
Myocardial blood flow. Myocardial blood flow, expressed
as ml/min per g, was measured in the area of coronary
occlusion as well in the contralateral area. Flows are shown
for the subendocardial and subepicardial regions (Fig. 3).
There was no difference in myocardial blood flow at baseline
or during ischemia. There was practically no flow in the
occluded area during ischemia, indicating the absence of
collateral blood flow. At reperfusion, the flow was signifi-
cantly reduced in groups 1, 3, and 4. In group 2, myocardial
blood flow was normal during reperfusion.
There were no changes in myocardial blood flow in the
control areas throughout the experiment.
Infarct size. Myocardial infarct size is shown in Figure 4.
The area at risk was small (15% of LV mass) and constant
among all groups. There was a significant reduction in
infarct size in the supported groups. The group supported
throughout ischemia as well as reperfusion showed the most
explicit reduction in infarct size (control: 67.2  4.6%;
support group: 18.1  10%; p  0.00001). Both groups 3
and 4 showed a significant reduction in infarct size, as
compared with the control group.
To assess the relationship between oxygen consumption
and infarct size, independent of any intervention, we ana-
lyzed this relationship for the total group of tested animals
(Fig. 5). The relationship is plotted for oxygen consumption
during ischemia and for oxygen consumption during reper-
fusion. There is a strong correlation between infarct size and
myocardial oxygen consumption during reperfusion, regard-
less of the animals’ treatment (r  0.9).
DISCUSSION
In the management of acute MI, the primary focus has been
to achieve early reperfusion. This intervention can reduce
infarct size considerably, but the time restraints remain very
important (22,23). When reperfusion is delayed, infarct size
is significant. Several groups have shown beneficial effects of
mechanical unloading during acute MI (24–28). Complete
unloading using cardiopulmonary bypass, LV venting, and
cardioplegia before reperfusion led to a 77% reduction of
infarct size (24). This technique is not applicable as a
primary approach for MI.
A more practical approach is the use of counterpulsation.
Diastolic augmentation by intra-aortic balloon pumping has
been shown to increase myocardial blood flow and myocar-
dial oxygen supply (29). Some series have indicated that this
increased myocardial blood flow leads to significant reduc-
Table 1. Hemodynamic Evolution During Ischemia and Reperfusion
Heart Rate
(beats/min)
Cardiac Output
(l/min)
Pump Flow
(l/min)
Mean ABP
(mm Hg)
LVEDP
(mm Hg)
dP/dtmax
(mm Hg/s)
dP/dtmin
(mm Hg/s)
LAP
(mm Hg)
Baseline
Group 1 91  9 4.7  0.6 — 78  8 10.1  1.1 1,624  203 1,773  165 9.1  0.5
Group 2 93  4 4.7  0.8 — 78  4 11.1  1.8 1,559  163 1,769  78 9.9  0.9
Group 3 89  9 4.7  0.7 — 78  5 10.4  1.3 1,602  161 1,784  265 10  2.1
Group 4 91  9 4.4  0.4 — 76  2 9.3  1.0 1,592  262 1,935  222 8.4  0.8
During ischemia
Group 1 90  6 4.5  0.7 — 73  6 11.6  1.2 1,422  115 1,541  180 10.5  0.7
Group 2 93  2 4.6  0.6 4.1  0.4 83  4* 7.1  1.7* 1,032  153* 1,192  218* 6.3  2.0*
Group 3 91  10 4.5  0.6 — 74  5 11.2  1.0 1,507  122 1,507  227 10.7  1.8
Group 4 90  8 4.3  0.3 — 73  3 10.9  1.9 1,436  164 1,568  140 10.1  2.0
During reperfusion
Group 1 93  10 4.1  0.5 — 66  7 11  1.7 1,264  137 1,447  293 10  1.4
Group 2 94  5 4.4  0.5 4.1  0.4 77  4* 7.3  1.4* 1,005  189* 1,079  122* 6.4  1.5*
Group 3 91  6 4.5  0.4 4.1  0.4 78  3* 7.2  0.7* 1,023  86* 1,100  122* 6.8  1.0*
Group 4 92  5 4.3  0.3 2.4  0.1 74  2* 8.7  1.4 1,201  111 1,287  132 7.9  1.4
*Significant difference compared with the control group (Student t test). Data are presented as the mean value  SD.
ABP  arterial blood pressure; LAP  left atrial pressure; LVEDP  left ventricular end-diastolic pressure; dP/dt  first derivative of left ventricular pressure; Group 1 
no support; Group 2  support during ischemia and reperfusion; Group 3  support during reperfusion; Group 4  partial support during reperfusion.
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Figure 2. Myocardial metabolism during ischemia and reperfusion for the four different groups: control group (squares), fully supported group (circles),
group supported during reperfusion only (diamonds), and group with partial support during reperfusion (). *Significant difference (analysis of variance
with Newman-Keuls post-hoc testing: p 0.05) compared with the control group. Mechanical support influences myocardial oxygen consumption (MVO2)
(upper panel). There was a significant reduction of oxygen consumption in all supported groups at all supported times. The lactate extraction ratio (LER)
(lower panel) was significantly reduced during ischemia in all groups, except for the fully supported group. At reperfusion, the LER increased again, but
the differences are not significant.
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Figure 3. Myocardial blood flow in the subendocardial (upper panel) and subepicardial (lower panel) regions of the occluded area for the different groups
(control group represented by open bars; fully supported group  darker shaded bars; group supported in reperfusion only  lighter shaded bars; and
group with partial support during reperfusion  solid bars). During occlusion, there was almost no flow in either of the groups. At reperfusion, the fully
supported group was the only group to show normal myocardial perfusion. BS  baseline; occl  during coronary occlusion; reperf  reperfusion.
*Significant difference (Student t test) compared with the baseline value. #Significant difference (Student t test) compared with the control group.
Figure 4. Myocardial infarct sizes of the four different groups: 1 control group; 2 full support during ischemia and reperfusion; 3 full support during
reperfusion only; 4  partial support during reperfusion only. The open bars indicate the area at risk; solid bars indicate infarct size. The intervals indicate
the standard deviation of the mean value. *Significant difference (Student t test) compared with the control group.
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Figure 5. Correlations between myocardial oxygen consumption (MVO2) during ischemia (upper panel) and during reperfusion (lower panel) and the final
infarct size of each animal. Infarct size correlated better with MVO2 during reperfusion. The intervals indicate the 95% confidence intervals. Solid lines
and circles represent the regression with 95% confidence limits.
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tions of infarct size in experiments of acute MI in canine
models (30,31). However, studies performed in other than
canine models have showed that intra-aortic balloon pump-
ing does not lead to a significant reduction of infarct size
(32,33). Studies with the Hemopump (Medtronic, Minne-
apolis, Minnesota) showed that support with a miniaturized
transvalvular LV assist device results in increased myocardial
perfusion in ischemic areas (34,35). Unloading the heart
with the Hemopump resulted in a reduction of infarct size
from 62.6% in the control group to 21.7% in the supported
group in a canine infarction model (28).
Most of the studies investigating the role of mechanical
support during MI were performed in dogs and show
increased myocardial perfusion. It is well established that
the collateral circulation is a major determinant of infarct
size in dogs (36). However, the degree of collateral circula-
tion in patients varies enormously and most often is not
predictable. We studied the effect of unloading in the ovine
heart, as it has no preexisting coronary collateral vessels, its
infarctions have sharply defined borders, and coronary
anatomy varies little between sheep (37–39). In addition, we
opted for a small myocardial area at risk to avoid the
confounding effect of cardiogenic shock and to study the
unloading capacities of the device.
As a consequence, the hemodynamic effects of ischemia
are very limited, allowing a stable experimental protocol.
The observed hemodynamic effects of the microaxial pump
are therefore predominantly unloading and an increase of
the diastolic (and consequently the mean) BP. This unload-
ing resulted in a significant reduction of infarct size, as
shown by TTC staining. The reduction of infarct size is
significant for all groups supported by the microaxial pump.
The effect is most dramatic for the group supported during
ischemia and reperfusion. The measured infarct sizes in the
different groups are in accordance with the significant
reduction in subendocardial blood flow during reperfusion
in these animals—described as the “no-reflow phenome-
non” (40). In contrast, the animals supported fully through-
out the experiment with the microaxial blood pump showed
normal subendocardial perfusion during reperfusion.
The mechanism of the observed salvage of myocardial
tissue can be double: myocardial perfusion is increased in
the area at risk through collateral circulation and the
metabolic needs are reduced. During support, the mean
perfusion pressure and especially the diastolic perfusion
pressure were significantly increased in all groups. Secondly,
the end-diastolic LV pressure was lower in all groups
supported with the microaxial pump. However, with total
coronary occlusion, blood flow in the ischemic area should
be provided by preexisting collateral circulation, and this is
known to be almost absent in healthy sheep. In addition, we
measured no increase in myocardial perfusion in the isch-
emic area of the supported animals.
The observed reduction in myocardial oxygen consump-
tion is significant and directly related to the degree of
mechanical support. As a consequence, the reduction in
infarct size correlates with the reduction in oxygen con-
sumption. In addition, the LER in the supported group was
almost normal during ischemia. Therefore, the reduction in
metabolic need is the major mechanism of the observed
reduction in infarct size in this series.
An important parameter of infarct size is the size of the
area at risk (36). Small areas have relatively more collateral
flow and are more resistant to ischemia. However, the
mechanism of myocardial salvage, as shown in this study, is
based on a reduction of myocardial oxygen consumption and
not on an increase in collateral flow. Therefore, we expect
that the shown benefits are present in all infarcts, irrespec-
tive of their size. The hemodynamic effect of this pump
(increased diastolic BP and decreased filling pressure) sug-
gests that myocardial perfusion will also benefit patients
with existing collateral circulation. Previous studies on
myocardial perfusion in the ovine model with stenotic (not
occluded) vessels showed that the microaxial pump increases
myocardial flow in ischemic areas in a more efficient way
than balloon counterpulsation (35).
Clearly, the beneficial effect of the pump depends also on
the degree of support. We specifically tested the effect of the
so-called “partial support,” as it is technically possible to
provide this flow with the percutaneous device (outer
diameter 4 mm). The larger pump has an outer diameter of
6.4 mm and requires a surgical cut-down of the femoral
artery to allow safe introduction. Although a cut-down is
acceptable in terms of invasiveness, it influences the avail-
ability and practicality of the approach.
The clinical application of this pump is dual: the pump
supports the failing circulation (treatment of shock pa-
tients), and early unloading results in a reduction of infarct
size.
Although animals supported during reperfusion had a
significant reduction of infarct size, our data indicate that
myocardial salvage is better when the heart is supported
early (during ischemia). In the clinical setting of acute MI,
reperfusion is often achieved late (41). Salvage of myocytes
after MI is believed to be possible in the first 6 h after the
onset of ischemia.
Prolonged unloading with administration of nitrates
proved beneficial for ventricular function, even after late
reperfusion (42,43). Technically, the pump can be used
safely for seven days. However, the benefit of prolonged
mechanical unloading is undone by the inevitable immobi-
lization of the patient, instrumented with a pump through
the femoral artery. Therefore, the major benefit of myocar-
dial unloading with the micropump in acute MI is to be
found in the first hours of reperfusion or, if at all possible,
during ischemia.
Conclusions. Support with the Impella microaxial blood
pump reduces the infarct size in an animal model. The
mechanism of this effect is based on a reduction in meta-
bolic need. The effect of this unloading is stronger when
applied early (during ischemia) and is related to the degree
of unloading.
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